Lucid Diagnostics

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company based in New York, incorporated in 2018 and operating as a subsidiary of PAVmed Inc. The company focuses on the early detection of esophageal cancer, particularly for patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and esophageal adenocarcinoma. The flagship product of Lucid Diagnostics is the EsoGuard Esophageal DNA Test, which is performed using the EsoCheck Esophageal Cell Collection Device. This non-invasive test aims to enable early detection of esophageal precancer, helping to prevent deaths from esophageal adenocarcinoma. The EsoCheck device has received FDA 510(k) clearance, and the EsoGuard test has been granted Breakthrough Device Designation by the FDA. Lucid Diagnostics operates a CLIA-certified, CAP-accredited clinical laboratory, LucidDx Labs Inc., which processes these tests and has received Medicare payment determination for the EsoGuard DNA test. Lucid Diagnostics is dedicated to empowering clinicians to save lives through early detection and treatment, with a mission to significantly reduce mortality rates associated with esophageal cancer. The company is publicly traded on NASDAQ under the ticker symbol LUCD.

• Employees 72
• Founded 2018
• Annual Revenue $4173000
• Total Funding $161850000